1800 244 735

Could molecular handcuffs lower the protein that causes Huntington's disease?

Several approaches are being taken to lower the amount of the toxic huntingtin protein as a way to treat Huntington’s disease. Last week, a study reported a new strategy that helps target huntingtin for disposal by the cell. This approach is in its earliest stages and requires more testing, but the concept is sure to be investigated further.

Nipping the problem in the bud

The one good thing we can say about Huntington’s disease is that, unlike many neurodegenerative diseases, we know the exact culprit: the huntingtin gene. Everyone has the huntingtin gene, but people with HD have an expansion in theirs.

The huntingtin gene acts as a recipe for the huntingtin protein, a molecular machine with many jobs in the cell. When a person inherits an expanded huntingtin gene, there’s a corresponding expansion in their huntingtin protein. For reasons that are not entirely understood, this expanded, or ‘mutant’ protein is toxic to brain cells.

Since we know the exact cause of HD, many treatment approaches aim to nip the problem in the bud: lower the amount of toxic mutant huntingtin protein. The most advanced of these approaches are already in clinical trials (read about them here). But researchers aren’t stopping there – many other approaches are being investigated (read about them here).

A new approach

A study published in the journal Nature last week reported a possible new way to lower mutant huntingtin levels. Researchers turned to one of the cell’s waste management systems, called ‘autophagy’. Autophagy is an orderly way for cells to recycle unnecessary or damaged parts. The unwanted parts are swallowed up by big bags of digestive juices, and broken down, just like garbage bags left on the curb are thrown into a city garbage truck and hauled away.

Imagine if we had a set of molecular ‘handcuffs’ that could tether the mutant huntingtin protein to the garbage truck? Then it would always be cleaned up, with no chance to accumulate and cause problems in the cell. That’s exactly what a research team from Shanghai set out to find.

Molecular handcuffs with the right fit

The team started their search with a list of existing drug candidates – things like FDA-approved drugs and natural remedies. This is called a drug library. They stamped each of the small molecules into tiny, clean-cut dots arranged in a grid on a glass dish.

Then they turned to a protein called LC3, which is in charge of capturing cargo destined for disposal in the cell. LC3 is like the garbage collector who hangs off the back of the truck, methodically picking up garbage bags around the neighbourhood and dumping them into the compactor.

In the study, the LC3 protein was passed over the plate of small molecules in hopes that some of the small molecules would fit the shape of LC3, latch on, and stick LC3 onto the dish.

The same process was then done with mutant huntingtin, with some of the small molecules fitting its shape, latching on, and binding mutant huntingtin to the plate.

A fancy light-bouncing technique was then used to detect any dots on the plate that had captured both proteins – mutant huntingtin and LC3. The molecules in these dots were the first candidate molecular handcuffs that could link mutant huntingtin to the LC3 garbage collector.

To further refine the search, normal (non-expanded) huntingtin protein was also passed over the plate, with the purpose of ruling out any molecules that bound to normal huntingtin. The reason for this is that normal huntingtin has many important functions in the cell, so it makes sense to search for drugs that selectively lower the toxic mutant huntingtin, leaving normal huntingtin alone.

Although the research team started with a relatively short list of small molecules for a study of this type, they were apparently lucky enough to find not one, but two that stuck to both mutant huntingtin and LC3. Based on the chemical structures of these ‘hits’, they then came up with two more potential mutant huntingtin-LC3 handcuffs, for a total of four.

Do the handcuffs help get rid of of huntingtin?

The candidate molecules were first tested in cells grown in a dish. From HD mouse model brain cells, to skin cells from HD patients, to HD patient cells that have been converted to neurons, the molecules appeared to lower the amount of mutant huntingtin while leaving normal huntingtin alone. The same was true in a fruit fly model of HD, and three of the four candidates even reduced mutant huntingtin when injected into the brains of HD model mice.

HD patient cells, grown in a dish and converted to neurons, usually die more easily than those from a person without HD. The candidate small molecules improved this somewhat, and also increased the lifespan and climbing ability of HD model fruit flies. In model mice, some HD-like symptoms were also improved.

Does this mean we have a treatment for HD?

As we have reiterated many times here at HDBuzz, mice are not people and so far, every potential drug that worked in mice has failed in humans. The excitement behind this study lies in the idea of tethering mutant huntingtin to the cellular waste disposal system, an idea that is sure to be followed up and refined as the research moves forward.

It is also an approach that could work really well in combination with others that are already being tested. Just as a bath will empty faster if you turn off the faucet and pull out the plug, so reducing the manufacture of huntingtin protein and speeding up its removal from cells could be a powerful combo.

One thing raising eyebrows among HD drug-hunters about this study is just how lucky the team was to find two molecules that did what they wanted, even though the library they started with wasn’t enormous. That doesn’t mean the results are untrue, but it could mean that the test of handcuff stickiness was easier to pass than they thought. If so, there might be unanticipated “off-target” effects if the molecules they found are generally sticky, and just happened to stick more to mutant huntingtin and LC3 than to healthy huntingtin.

All this calls for what one of our particularly smart friends called “orthogonal validation”. That means that the handcuff molecules need to be tested by an independent team of researchers, to double check that they are as good as they sound, and to check for any potential downsides that the first team might have missed.

Since the molecular handcuffs identified in this study are already available to HD researchers everywhere, you can bet they will be added to laboratory tool sets around the world.

Latest Research Articles

Understanding expansions at the single cell level

Published date: 12 March, 2024

In two recent studies, researchers looked at how different parts of the brain are affected by CAG expansions in Huntington’s disease (HD) at the level of individual brain cells. The scientists looked at post-mortem brains from people with and without HD to track molecular changes in different brain regions called the cortex and striatum. These ... Read more

Huntington's Disease Therapeutics Conference 2024 – Day 3

Published date: 7 March, 2024

HDBuzz is back for the last day of the CHDI HD Therapeutics Conference: Thursday February 29th in Palm Springs, California. This article summarizes our real-time updates of the conference in community-friendly language. From genes to medicines The morning session will focus on how human genetics is driving the development of therapeutics. “Genetic modifiers” are genes ... Read more

Huntington's Disease Therapeutics Conference 2024 – Day 2

Published date: 6 March, 2024

HDBuzz is back for Day 2 of the CHDI HD Therapeutics Conference: Wednesday February 28th in Palm Springs, California. This article summarizes our real-time updates of the conference in community-friendly language. It’s a brain disease This morning’s session is titled “It’s a brain disease” and will feature talks about BRAINSSSS! HD scientists are a bit ... Read more

Huntington's Disease Therapeutics Conference 2024 – Day 1

Published date: 5 March, 2024

The HDBuzz team recently convened in Palm Springs, California, along with hundreds of other scientists from all over the globe, for the 19th Annual HD Therapeutics Conference, hosted by the HD research foundation CHDI. From Tuesday February 27th through Thursday February 29th, we live-tweeted dozens of scientific talks by world experts in Huntington’s disease research, ... Read more

CRISPR-based drugs: one giant leap for mankind

Published date: 14 February, 2024

You’ve likely heard of CRISPR. By now, you also may have heard that CRISPR has been used to produce a revolutionary new treatment for Sickle Cell Disease. Just 4 years after the Nobel Prize for the discovery of CRISPR was awarded, we have an approved treatment using this technology. This may have you wondering if ... Read more

Making babies: having a family, the HD way

Published date: 11 January, 2024

For people at risk of Huntington’s disease, having a baby who might inherit HD can make decisions around planning a family extremely difficult. This article explains the options available, and how modern reproductive science can make a difference right now to families touched by HD. Content warning This article describes issues of fertility, tough choices, ... Read more